Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.
Konstantinov, K, von Mikecz, A, Buchwald, D et al. · The Journal of clinical investigation · 1996 · DOI
Quick Summary
Researchers found that about half of ME/CFS patients had antibodies (immune proteins) in their blood that attack a protein called lamin B1 found in the nucleus of cells. This suggests that ME/CFS may involve the immune system mistakenly attacking the body's own cells. This discovery provides evidence that autoimmunity—when the body's defense system malfunctions—may play a role in ME/CFS.
Why It Matters
This study offers objective laboratory evidence that autoimmunity may be involved in ME/CFS pathophysiology, supporting the biological basis of the disease and potentially opening avenues for autoimmune-targeted diagnostics or therapies. Identifying specific autoantibodies could eventually help distinguish ME/CFS from other fatigue-related conditions and stratify patients for targeted treatment approaches.
Observed Findings
Approximately 52% of ME/CFS patient sera reacted with nuclear envelope antigens detected by immunofluorescence microscopy
Immunoblot analysis and immunoprecipitation identified IgG autoantibodies targeting lamin B1, a nuclear envelope protein
Autoantibodies were characterized as IgG isotype, indicating a humoral immune response
Nuclear rim staining pattern was observed on immunofluorescence, consistent with nuclear envelope localization
Inferred Conclusions
The presence of autoantibodies to a conserved intracellular protein (lamin B1) provides new laboratory evidence for an autoimmune component in ME/CFS
The high prevalence of anti-nuclear envelope autoantibodies (52%) suggests autoimmunity may be a significant pathophysiologic mechanism in a substantial subset of ME/CFS patients
The IgG isotype indicates a persistent, adaptive humoral immune response against nuclear proteins in affected individuals
Remaining Questions
Are these lamin B1 autoantibodies present in healthy controls or other disease states, and what is their specificity and sensitivity for ME/CFS diagnosis?
Do these autoantibodies correlate with disease severity, symptom profiles, or clinical outcomes in ME/CFS?
What This Study Does Not Prove
This study does not prove that lamin B1 autoantibodies cause ME/CFS—it demonstrates only an association. It does not establish whether these autoantibodies are a cause, consequence, or epiphenomenon of disease. The study also does not address whether these autoantibodies are present in other illnesses or healthy individuals, limiting conclusions about disease specificity.
What mechanisms drive the loss of immune tolerance to lamin B1, and do these autoantibodies functionally impair nuclear envelope integrity or cellular processes?
Are additional nuclear envelope proteins or other intracellular antigens targeted by autoantibodies in ME/CFS patients?